Prevention of abnormalities of hemostasis and vte in ovarian cancer patients, undergoing chemotherapy

O.V. Somonova; A.V. Madzhuga; A.L. Elizarova; D.N. Kushlinskii; I.I. Matveeva

Prevention of abnormalities of hemostasis and vte in ovarian cancer patients, undergoing chemotherapy

O.V. Somonova¹, A.V. Madzhuga², A.L. Elizarova³, D.N. Kushlinskii⁴, I.I. Matveeva⁵

research article Pages: 43-47

Keywords: ovarian cancer hemostasis thrombosis LMWH

Abstract

Cancer tumor elevates risk of venous thromboembolism (VTE) and pulmonary embolism in 4 - 7 time. Abnormalities of hemostasis system, activate tumor and chemotherapy, plays base role in pathogenesis of VTE in ovarian cancer patients. The use of LMWH in chemotherapy reduces the activation of pro-coagulation (aPTT, prothrombin, von Willebrand factor) and platelet links of hemostasis system. LMWH conduces preservation of natural inhibitor of thrombin, maintains the defensive role of fibrinolysis. The VTE was 22 % in the control group and 5 % in the LMWH group. Rise of concentration of fibrinogen, D-dimer, von Willebrand factor are hemostasis factors prognosis of development cancerous process.

How to cite

Сомонова О.В., Маджуга А.В., Елизарова А.Л., Кушлинский Д.Н., Матвеева И.И. Профилактика нарушений гемостаза и тромботических осложнений у больных раком яичников, получавших химиотерапию // Технологии живых систем. 2012. № 9. С. 43–47.

References

Agnelli G., Verso M. Management of venous thromboembolism in patients with cancer // J. Thromb. Haemost. 2011. V. 9 (Suppl. 1). P. 316 - 324.
Nicolaides A.N. et al.Prevention and treatment of venous thromboembolism. International Consensus Statement. Guidelines according to scientific evidence // Int. Angiol. 2006. V. 25. P. 101 - 161.
Ten C.H., Falanga A. Overview of the postulated mechanisms linking cancer and thrombosis // Pathophysiol. Haemost. Thromb. 2007. V. 36. P. 122 - 130.
Arcelus J.I. Recognizing the risk of VTE in surgical patients // Int. Surg. Thromb. Meeting «Optimizing VTE Management in surgical patients» (abstract). Greece. 2007.
Rodriguez A.O., Wun T., Chew H., Zhou H. et al. Venous thromboembolism in ovarian cancer // Gynecol. Oncol. 2007. V. 105. № 3. P. 784 - 790.
Lip G.Y., Chin B.S., Blann A.D. Cancer and the prothrombotic state // Lancet Oncol. 2002. V. 3. P. 26 - 34.
Amin C., Mackman N., Key N.C. Microparticles and cancer // Pathophysiol. Haemost.Thromb. 2008. V. 36. P. 177 - 183.
Buller H.R., van Doormaal F.F., van Sluis G.l. et al.Cancer and thrombosis: from molecular mechanism to clinical presentations // J. Thromb. Haemost. 2007. V. 5 (Suppl. 1). P. 246 - 254.
Petralia G.A., Lemoine N.R., Kakkar A.K. Mechanisms of disease: the impact of antithrombotic therapy in cancer patients // Nat. Clin. Pract. Oncol. 2005. V. 2. P. 356 - 563.
Agnelli G., Verso M. Thromboprophylaxis during chemotherapy in patients with advanced cancer // J. Thromb. Haemost. 2010. V. 125 (Suppl. 2). P. 17 - 20.
Kuderer N.M., Khorana A.A., Lyman G.H. et al. A meta-analysis and systematic review of
the efficacy and safely of anticoagulants as cancer treatment: impact on survival and bleeding complications // Cancer. 2007. V. 110. P. 1149 - 1161.

[1] Agnelli G., Verso M. Management of venous thromboembolism in patients with cancer // J. Thromb. Haemost. 2011. V. 9 (Suppl. 1). P. 316 - 324.

[2] Nicolaides A.N. et al.Prevention and treatment of venous thromboembolism. International Consensus Statement. Guidelines according to scientific evidence // Int. Angiol. 2006. V. 25. P. 101 - 161.

[3] Ten C.H., Falanga A. Overview of the postulated mechanisms linking cancer and thrombosis // Pathophysiol. Haemost. Thromb. 2007. V. 36. P. 122 - 130.

[4] Arcelus J.I. Recognizing the risk of VTE in surgical patients // Int. Surg. Thromb. Meeting «Optimizing VTE Management in surgical patients» (abstract). Greece. 2007.

[5] Rodriguez A.O., Wun T., Chew H., Zhou H. et al. Venous thromboembolism in ovarian cancer // Gynecol. Oncol. 2007. V. 105. № 3. P. 784 - 790.

[6] Lip G.Y., Chin B.S., Blann A.D. Cancer and the prothrombotic state // Lancet Oncol. 2002. V. 3. P. 26 - 34.

[7] Amin C., Mackman N., Key N.C. Microparticles and cancer // Pathophysiol. Haemost.Thromb. 2008. V. 36. P. 177 - 183.

[8] Buller H.R., van Doormaal F.F., van Sluis G.l. et al.Cancer and thrombosis: from molecular mechanism to clinical presentations // J. Thromb. Haemost. 2007. V. 5 (Suppl. 1). P. 246 - 254.

[9] Petralia G.A., Lemoine N.R., Kakkar A.K. Mechanisms of disease: the impact of antithrombotic therapy in cancer patients // Nat. Clin. Pract. Oncol. 2005. V. 2. P. 356 - 563.

[10] Agnelli G., Verso M. Thromboprophylaxis during chemotherapy in patients with advanced cancer // J. Thromb. Haemost. 2010. V. 125 (Suppl. 2). P. 17 - 20.

[11] Kuderer N.M., Khorana A.A., Lyman G.H. et al. A meta-analysis and systematic review of
the efficacy and safely of anticoagulants as cancer treatment: impact on survival and bleeding complications // Cancer. 2007. V. 110. P. 1149 - 1161.

Abstract

How to cite

Related articles